10-Q: United-Guardian Inc. Reports Mixed Results in Q3 2024, Driven by Cosmetic Ingredient Sales

United-Guardian Inc. saw a slight increase in net sales for the third quarter of 2024, with significant growth in cosmetic ingredient sales offsetting declines in pharmaceutical sales.

Summary

• United-Guardian Inc. reported a marginal increase in net sales for the third quarter of 2024, rising to $3,060,113 from $3,057,518 in the same period last year.
• However, net sales for the first nine months of 2024 showed a more substantial increase of 17%, reaching $9,705,262 compared to $8,278,141 in 2023.
• The company's cosmetic ingredient sales saw a significant increase of 8% in Q3 and 68% for the first nine months of 2024, primarily driven by sales to ASI, with a large portion of those sales going to customers in China.
• Pharmaceutical sales experienced a decrease of 6% in Q3 and 11% for the first nine months of 2024, due to a temporary shutdown at the company's contract manufacturer earlier in the year.
• Medical lubricant sales saw a slight decrease of 2% in Q3 but increased by 4% for the first nine months of 2024.
• Cost of sales decreased as a percentage of sales to 46% in Q3 2024, down from 57% in Q3 2023, and to 47% for the first nine months of 2024, down from 52% in 2023, due to a higher proportion of cosmetic ingredient sales.
• Operating expenses increased by 21% in Q3 and 12% for the first nine months of 2024, primarily due to higher board fees and payroll expenses.
• Net income for the third quarter of 2024 was $865,484, or $0.19 per share, compared to $626,756, or $0.14 per share, in the same period last year.
• Net income for the first nine months of 2024 was $2,747,151, or $0.60 per share, compared to $1,843,931, or $0.40 per share, in the same period last year.
• The company declared and paid dividends of $0.25 per share in Q1 and $0.35 per share in Q3, totaling $2,756,323 for the first nine months of 2024.
• The company's working capital decreased slightly to $10,609,401 at September 30, 2024, from $10,718,457 at December 31, 2023.

Sentiment

Score: 7

Explanation: The document shows positive growth in key areas like cosmetic ingredient sales and net income, but there are also some concerns about pharmaceutical sales and supply chain risks. Overall, the sentiment is cautiously optimistic.

Positives

• The company experienced strong growth in cosmetic ingredient sales, particularly in the Asian market.
• The cost of sales as a percentage of sales decreased, indicating improved profitability.
• Net income and earnings per share increased significantly compared to the same periods in the previous year.
• The company's investment income increased due to a strategic shift towards U.S. Treasury Bills and Certificates of Deposit.
• The company has a strong working capital position and believes it is sufficient to support operations for at least the next twelve months.

Negatives

• Pharmaceutical sales declined due to a temporary shutdown at the contract manufacturer.
• Operating expenses increased due to higher board fees and payroll expenses.
• The company's working capital and current ratio decreased slightly.
• The company is facing supply chain instability due to military conflicts in the Middle East, which could impact future gross margins.

Risks

• The company is exposed to supply chain disruptions due to ongoing military conflicts and severe weather events.
• The company relies on a few major raw material suppliers, which could pose a risk if any of those suppliers experience disruptions.
• The company's pharmaceutical product, Renacidin, is manufactured by a single contract manufacturer, which could impact revenue if there are any disruptions.
• The company faces competition in the marketplace for some of its products, which are often sold at lower prices.
• The company is subject to changes in government drug rebate programs, which could impact its pharmaceutical sales.

Future Outlook

The company anticipates beginning manufacturing and reporting sales of its new line of sexual wellness products in 2025. The company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of growth opportunities.

Management Comments

• The company is working closely with its suppliers regarding lead times and continues to closely monitor the supply chain situation.
• The company has invested additional resources to better understand the market for its pharmaceutical products and will continue to invest resources to broaden market awareness.
• The company's management and Board of Directors continue to closely monitor the company's investment portfolio, and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on the company's financial position that the volatility of the global financial markets may have.

Industry Context

The company's focus on developing natural and environmentally friendly products aligns with the growing demand for sustainable products in the cosmetic industry. The company's expansion into the sexual wellness market is a strategic move to diversify its product offerings. The company's reliance on a few major distributors and suppliers is a common practice in the industry, but it also poses a risk if any of those partners experience disruptions.

Comparison to Industry Standards

• United-Guardian's reliance on a few key distributors, such as ASI, is common in the specialty chemical and ingredient industry, similar to companies like Croda International and Evonik Industries, which also rely on distributors for market reach.
• The company's focus on natural and sustainable ingredients mirrors the trend seen in the personal care industry, where companies like Givaudan and International Flavors & Fragrances (IFF) are also investing in these areas.
• The company's pharmaceutical sales are subject to government rebates and discounts, which is a common practice in the pharmaceutical industry, similar to companies like Teva Pharmaceuticals and Mylan (now Viatris).
• The company's gross margin improvement due to increased cosmetic ingredient sales is a positive sign, as companies in the specialty chemical sector often have higher margins in niche markets compared to commodity products.
• The company's investment strategy of shifting from equity mutual funds to U.S. Treasury Bills reflects a conservative approach, which is common among smaller companies seeking to preserve capital in uncertain economic times.

Related Party Transactions

• The company made payments of $20,000 to Ken Globus, the company's former President, for consulting services during the nine-month period ended September 30, 2024.
• The company made payments of $14,750 to the accounting firm PKF O'Connor Davies for accounting and tax services during the nine-month period ended September 30, 2024. Lawrence Maietta, a partner at PKF, is a director of the company.

Stakeholder Impact

• Shareholders will benefit from increased net income and dividends.
• Employees may benefit from increased payroll and payroll-related expenses.
• Customers may experience some supply chain disruptions due to ongoing military conflicts and severe weather events.
• Suppliers may experience increased demand for raw materials.
• Creditors may see a slight decrease in the company's working capital and current ratio.

Next Steps

• The company anticipates beginning manufacturing and reporting sales of its new line of sexual wellness products in 2025.
• The company expects to complete the building sprinkler system upgrade and roof replacement project by the end of 2024.
• The company will continue to monitor the supply chain situation and work closely with its suppliers.
• The company will continue to invest resources to broaden market awareness for its pharmaceutical products.

Key Dates

Keywords

cosmetic ingredients, pharmaceuticals, medical lubricants, net sales, net income, dividends, supply chain, Renacidin, Lubrajel, ASI